Clinical trial NCT01415791: Oral Mucosal Absorption of ICI176,334-1
Official title: Oral Mucosal Absorption of ICI176,334-1 in Japanese Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: oral mucosal absorption
pharmacokinetics
safety
bicalutamide
Japanese
healthy subject
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-08-12
Enrollment: 8
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the presence or absence of oral mucosal absorption of ICI176,334-1

Detailed description: Oral mucosal absorption of ICI176,334-1 in Japanese healthy male subjects

Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated, written informed consent prior to any study specific procedures
* Japanese healthy male subjects aged 20 to 45 years
* Male subjects should be willing to use barrier contraception ie, condoms, until 3 months after the last dose of investigational product
* Have a body mass index (BMI) between 17 and 27 kg/m2
* Eligible based on the physical findings, supine BP, pulse rate, ECG and laboratory assessments, as judged by the investigator(s)

Exclusion Criteria:

* Presence of any disease under medical treatment
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunological, blood, endocrine, neurological or mental disease to interfere with absorption, distribution, metabolism or excretion of drugs judged by investigator(s)
* Presence of any infectious disease, such as bacteria, virus and fungus Presence of allergic disorder, such as asthma, pollen disease or atopic dermatitis, and judged as necessary any medical treatment
* Any large surgical history of gastrointestinal tract such as gastric/intestinal resection or suturation

Primary outcomes:
measure: To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma
timeFrame: Samples are taken at 72 hours after application of the investigational drug
measure: To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma
timeFrame: Samples are taken at 168 hours after application of the investigational drug
measure: To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva
timeFrame: Samples are taken at 72 hours after application of the investigational drug
measure: To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva
timeFrame: Samples are taken at 168 hours after application of the investigational drug
Secondary outcomes:
measure: To assess the safety by assessment of adverse event
timeFrame: Adverse Events will be captured starting from screening up to 14 to 21 days (follow-up)
measure: To evaluate the safety by evaluation of vital signs
timeFrame: Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug
measure: To evaluate the safety by assessment of electrocardiograms (ECGs)
timeFrame: Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug
Other outcomes:
Locations:
Study officials:
References: